More than 1 million Medicare beneficiaries had a diagnosis of opioid use disorder in 2020.1 However, fewer than 1 in 5 Medicare beneficiaries with an opioid use disorder (OUD) diagnosis received medication to treat this condition. In addition, the number of patients who stay in treatment after hospital discharge decrease drastically during the transition of care.2
This webinar series is a collaboration of all of the Quality Innovation Network-Quality Improvement Organizations and will provide strategies, interventions, and targeted solutions to ensure access to MOUD treatment and facilitate the continuity of care through the continuum. This series’ focus is ensuring MOUD treatment within nursing home/hospital care transitions, but is appropriate for all care settings, including nursing homes, clinics and hospital care teams and their partners.
Next Session: Management of Patients on MOUD During the Nursing Home Stay
Session 6 Management of Patients on MOUD During the Nursing Home Stay (Part 2: Panel Discussion) - March 8, 2024
Management of Patients on MOUD During the Nursing Home Stay
Admissions assessment & treatment, addressing stigma, and naloxone training.
Part 2: Panel Discussion | Friday, March 8, 2024 – 11:00 am CT
More and more nursing homes state that they are ill-equipped to face the needs of patients with multiple co-occurring conditions, such as mental health and substance use disorder. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), best practices for the care and treatment of patients with opioid use disorder (OUD) are not currently widely established in long-term care settings. 1
Please join us to learn more about how your nursing home could be better prepared to work with and provide continuity of care for patients with OUD.
Guest speakers will describe how to include OUD screening in your admission assessment, review the steps to ensure continuity and/or provide access to treatment for patients with OUD and learn more about how to recognize and manage a patient who is overdosing.
- Massachusetts Department of Public Health – The Care of Residents with Opioid & Stimulant Use Disorders in Long-Term Care Settings toolkit
Sessions 7 (Part 1: Presentation) and 8 (Part 2: Panel Discussion)—April 12, 2024 and May 10, 2024
Sustaining Recovery for Patients on MOUD
Alternatives to Opioids (ALTO), peer support, NA meetings, counseling, and use of technologies
Part 1: Formal Presentation
Part 2: Panel Discussion
Patients with pain should receive treatment that provides the greatest benefit. Opioids are not the first-line therapy for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. Evidence suggests that non-opioid treatments, including non-opioid medications and nonpharmacological therapies can provide relief to those suffering from chronic pain, and are safer. Patients receiving MOUD must be able to receive concomitantly counseling, along with medical, vocational, educational, and other assessment and treatment services. Providing a “whole-patient” approach to the treatment of substance use disorders can be challenging. This 2-part webinar will present federal, state, and local solutions to ensure a path to sustain recovery. Guest speakers will also share ideas on how to expand and strengthen the community response to the benefit of people with opioid use disorders and the entire community.
Session 9—June 7, 2024
Join us to hear the key takeaways of this series of webinars.
A general certificate of attendance will be provided for continuing education/contact hours. Attendees are responsible for determining if this program meets the criteria for licensure or recertification for their discipline.
PAST EVENT | Session 1 - Role of the Emergency Department (ED) Physician in the Treatment of Patients with OUD
Basics & science of addiction and screening & initiating MOUD
Emergency Physicians are active participants in the quest of solutions to identify patients at risk for substance abuse while using reasonable prescribing guidelines to address the legitimate pain reliefs needs of their patients.
Learn how to recognize opioid use disorder, identify withdrawal, and initiate MOUD in the ED.
Speaker: Bobby Redwood, MD, MPH, FACEP
PAST EVENT | Session 2 - Role of the Pharmacist in the Treatment of Patients with OUD
Medication processes, addressing opioid adverse drug events (ADEs), and risk assessment for opioid prescribing.
Kyla Newland, PharmD: Clinical Pharmacist and Account Manager with Mountain Pacific Quality Health
Megan Penner, PharmD, BCPS: Clinical Assistant Professor, L.S. Skaggs College of Pharmacy
Clinical Pharmacist, Mat Su Regional Medical Center
Jon Pouliot, MS, PharmD, BCPS: Associate Professor, Pharmacy and Pharmaceutical Sciences, Lipscomb University
Emergency Medicine Pharmacist, Williamson Medical Center
PAST EVENT | Session 3 - Seamlessly Transitioning Patients on MOUD to Nursing Homes
PAST EVENT | Session 4 - Seamlessly Transitioning Patients on MOUD to Nursing Homes
Session 4; Part 2: Panel Discussion
A well-planned transition of care ensures health care continuity, avoids preventable poor outcomes among patients with OUD, and co-occurring mental health disorders. Challenges and barriers persist especially during the transfer of patients to nursing homes.
PAST EVENT | Session 5 - Management of Patients on MOUD During the Nursing Home Stay
Questions? Contact: Tammy Wagner, RN, LSSGB; Great Plains Quality Innovation Network Quality Improvement Advisor, at firstname.lastname@example.org
1 Health and Human Services: Office of Inspector General. Combating the Opioid Epidemic OIG Report. May 18, 2023. Accessed on: August 2, 2023. Available at: https://oig.hhs.gov/reports-and-publications/featured-topics/opioids/
2 Klimas J, Hamilton M, et al. Retention in Opioid Agonist Treatment: A Rapid Review and Meta-Analysis Comparing Observational Studies and Randomized Controlled Trials. August 6, 2021. Available at: https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-021-01764-9